Literature DB >> 26654241

EGCG/gelatin-doxorubicin gold nanoparticles enhance therapeutic efficacy of doxorubicin for prostate cancer treatment.

Li-Chu Tsai1, Hao-Ying Hsieh1,2, Kun-Ying Lu3, Sin-Yu Wang3, Fwu-Long Mi3,4,5.   

Abstract

AIM: Development of epigallocatechin gallate (EGCG) and gelatin-doxorubicin conjugate (GLT-DOX)-coated gold nanoparticles (DOX-GLT/EGCG AuNPs) for fluorescence imaging and inhibition of prostate cancer cell growth. MATERIALS &
METHODS: AuNPs alternatively coated with EGCG and DOX-GLT conjugates were prepared by a layer-by-layer assembly method. The physicochemical properties of the AuNPs and the effect of Laminin 67R receptor-mediated endocytosis on the anticancer efficacy of the AuNPs were examined.
RESULTS: The AuNPs significantly inhibit the proliferation of PC-3 cancer cell and the enzyme-responsive intracellular release of DOX could be tracked by monitoring the recovery of the fluorescence signal of DOX.
CONCLUSION: Laminin 67R receptor-mediated delivery of DOX using the AuNPs enhanced cellular uptake of DOX and improved apoptosis of PC-3 cells.

Entities:  

Keywords:  EGCG; Lam 67R; MMP-2; cellular uptake; doxorubicin; drug release; gelatin; gold nanoparticles; prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26654241     DOI: 10.2217/nnm.15.183

Source DB:  PubMed          Journal:  Nanomedicine (Lond)        ISSN: 1743-5889            Impact factor:   5.307


  11 in total

Review 1.  The role of polyphenols in overcoming cancer drug resistance: a comprehensive review.

Authors:  Parisa Maleki Dana; Fatemeh Sadoughi; Zatollah Asemi; Bahman Yousefi
Journal:  Cell Mol Biol Lett       Date:  2022-01-03       Impact factor: 5.787

2.  Inhibition of prostate cancer growth using doxorubicin assisted by ultrasound-targeted nanobubble destruction.

Authors:  Xiaozhou Fan; Luofu Wang; Yanli Guo; Xingyu Xiong; Lianhua Zhu; Kejing Fang
Journal:  Int J Nanomedicine       Date:  2016-07-29

Review 3.  Nanoparticles as Theranostic Vehicles in Experimental and Clinical Applications-Focus on Prostate and Breast Cancer.

Authors:  Jörgen Elgqvist
Journal:  Int J Mol Sci       Date:  2017-05-20       Impact factor: 5.923

Review 4.  Green Tea Catechins for Prostate Cancer Prevention: Present Achievements and Future Challenges.

Authors:  Valeria Naponelli; Ileana Ramazzina; Chiara Lenzi; Saverio Bettuzzi; Federica Rizzi
Journal:  Antioxidants (Basel)       Date:  2017-04-05

5.  A dock derived compound against laminin receptor (37 LR) exhibits anti-cancer properties in a prostate cancer cell line model.

Authors:  Charles Samuel Umbaugh; Adriana Diaz-Quiñones; Manoel Figueiredo Neto; Joseph J Shearer; Marxa L Figueiredo
Journal:  Oncotarget       Date:  2017-12-13

6.  Colloidal Stability and Cytotoxicity of Polydopamine-Conjugated Gold Nanorods against Prostate Cancer Cell Lines.

Authors:  Nouf N Mahmoud; Hakam Aqabani; Suhair Hikmat; Rana Abu-Dahab
Journal:  Molecules       Date:  2021-02-28       Impact factor: 4.411

7.  L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.

Authors:  Jiali Li; Xue Jiang; Lihuan Shang; Zhen Li; Conglian Yang; Yan Luo; Daoyu Hu; Yaqi Shen; Zhiping Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

8.  Epigallocatechin Gallate Enhances Inhibition Effect of DDP on the Proliferation of Gastric Cancer BGC-823 Cells by Regulating p19Arf-p53-p21Cip1 Signaling Pathway.

Authors:  Mengya Xue; XiaoLv Liu; Bing Cheng; XingKai Rui; MingCai Wu; Jun Lv
Journal:  Asian Pac J Cancer Prev       Date:  2021-04-01

9.  Laminin Receptor-Mediated Nanoparticle Uptake by Tumor Cells: Interplay of Epigallocatechin Gallate and Magnetic Force at Nano-Bio Interface.

Authors:  Sheng-Chieh Hsu; Nian-Ping Wu; Yi-Ching Lu; Yunn-Hwa Ma
Journal:  Pharmaceutics       Date:  2022-07-22       Impact factor: 6.525

Review 10.  Bio-Inspired Protein-Based Nanoformulations for Cancer Theranostics.

Authors:  Yi Gou; Dandan Miao; Min Zhou; Lijuan Wang; Hongyu Zhou; Gaoxing Su
Journal:  Front Pharmacol       Date:  2018-04-27       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.